| Gene symbol | IL12A | Synonyms | CLMF, IL-12A, NFSK, NKSF1, P35 | Type of gene | protein-coding |
| Chromosome | 3 | Map location | 3q25.33 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | ||||
| Description | interleukin 12A | ||||
| Gene symbol | IL12B | Synonyms | CLMF, CLMF2, IL-12B, IMD28, IMD29, NKSF, NKSF2 | Type of gene | protein-coding |
| Chromosome | 5 | Map location | 5q33.3 | dbXrefs | |
| Description | interleukin 12B | ||||
| GTO ID | GTC0232 |
| Trial ID | NCT02345330 |
| Disease | Head and Neck Squamous Cell Carcinoma |
| Altered gene | IL-12A|IL-12B |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | Gene transfer |
| Treatment | Tavokinogene Telseplasmid|tavo|pIL-12 |
| Phase | Phase2 |
| Recruitment status | Terminated |
| Title | A Multicenter Phase II Trial of Intratumoral pIL-12 Electroporation in Treatment-Refractory Metastatic and Unresectable SCC of the Head and Neck |
| Year | 2015 |
| Country | United States |
| Company sponsor | OncoSec Medical Incorporated |
| Other ID(s) | OMS-I130 |
| Vector information | |||
|
|||
| Cohort 1 | |||||||||
|
|||||||||